Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures.

Tytuł:
Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures.
Autorzy:
Mukherjee S; Department of In Vitro Carcinogenesis and Cellular Chemotherapy, Chittaranjan National Cancer Institute, Kolkata 700026, India.
Kar A; Department of Signal Transduction and Biogenic Amines, Chittaranjan National Cancer Institute, Kolkata 700026, India.
Khatun N; Department of Signal Transduction and Biogenic Amines, Chittaranjan National Cancer Institute, Kolkata 700026, India.
Datta P; Department of In Vitro Carcinogenesis and Cellular Chemotherapy, Chittaranjan National Cancer Institute, Kolkata 700026, India.
Biswas A; Department of Signal Transduction and Biogenic Amines, Chittaranjan National Cancer Institute, Kolkata 700026, India.
Barik S; Department of In Vitro Carcinogenesis and Cellular Chemotherapy, Chittaranjan National Cancer Institute, Kolkata 700026, India.
Źródło:
Cells [Cells] 2021 Jul 29; Vol. 10 (8). Date of Electronic Publication: 2021 Jul 29.
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI
MeSH Terms:
Computer Simulation*
Autoimmune Diseases/*complications
Carcinoma, Hepatocellular/*etiology
Liver Cirrhosis/*complications
Liver Neoplasms/*etiology
Autoimmune Diseases/genetics ; Biomarkers ; Carcinoma, Hepatocellular/genetics ; Carrier Proteins/analysis ; Carrier Proteins/genetics ; Cholangitis, Sclerosing/complications ; Cholangitis, Sclerosing/genetics ; Computational Biology ; Diacylglycerol O-Acyltransferase/analysis ; Diacylglycerol O-Acyltransferase/genetics ; Gene Expression Profiling ; Gene Expression Regulation ; Humans ; Liver Cirrhosis/genetics ; Liver Cirrhosis, Biliary/complications ; Liver Cirrhosis, Biliary/genetics ; Liver Diseases/complications ; Liver Diseases/genetics ; Liver Neoplasms/genetics ; Membrane Proteins/analysis ; Membrane Proteins/genetics ; Oligonucleotide Array Sequence Analysis ; Thyroid Hormones/analysis ; Thyroid Hormones/genetics ; Transaminases/analysis ; Transaminases/genetics ; Ubiquitin-Protein Ligase Complexes/analysis ; Ubiquitin-Protein Ligase Complexes/genetics ; Thyroid Hormone-Binding Proteins
References:
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. (PMID: 31500650)
Cancers (Basel). 2014 Jan 13;6(1):79-111. (PMID: 24419005)
J Immunol Res. 2019 Nov 25;2019:9437043. (PMID: 31886312)
R Soc Open Sci. 2018 Dec 5;5(12):181006. (PMID: 30662724)
World J Gastroenterol. 2009 Jan 14;15(2):231-9. (PMID: 19132775)
BMC Bioinformatics. 2018 Dec 19;19(1):534. (PMID: 30567491)
Dev Biol. 2005 Jul 1;283(1):1-16. (PMID: 15907831)
Autoimmun Rev. 2002 Aug;1(4):220-5. (PMID: 12848999)
Cancers (Basel). 2020 Mar 10;12(3):. (PMID: 32164265)
Hepatol Int. 2017 Mar;11(2):171-180. (PMID: 28097530)
Proteomics. 2015 Aug;15(15):2597-601. (PMID: 25921073)
BMC Bioinformatics. 2013 Apr 15;14:128. (PMID: 23586463)
BMC Bioinformatics. 2015 May 22;16:169. (PMID: 25994840)
J Cell Mol Med. 2021 Jan;25(1):448-462. (PMID: 33215860)
Liver Cancer. 2013 Aug;2(3-4):367-83. (PMID: 24400224)
Dig Dis Sci. 2000 Oct;45(10):1944-8. (PMID: 11117564)
J Hepatol. 2014 Jan;60(1):210-23. (PMID: 24084655)
Hepatology. 1996 Aug;24(2):289-93. (PMID: 8690394)
World J Hepatol. 2015 May 8;7(7):926-41. (PMID: 25954476)
Immunol Lett. 2008 Oct 30;120(1-2):1-5. (PMID: 18694783)
Cancer. 1954 May;7(3):462-503. (PMID: 13160935)
Cancers (Basel). 2021 Mar 01;13(5):. (PMID: 33804480)
Nucleic Acids Res. 2009 Jan;37(Database issue):D623-8. (PMID: 18940869)
Nucleic Acids Res. 2011 Jan;39(Database issue):D712-7. (PMID: 21071422)
Liver Int. 2009 Aug;29(7):997-1009. (PMID: 19422482)
Clin Gastroenterol Hepatol. 2017 Aug;15(8):1207-1217.e4. (PMID: 28215616)
Sci Rep. 2018 Jun 15;8(1):9227. (PMID: 29907753)
Cell. 1999 Jul 9;98(1):37-46. (PMID: 10412979)
Ther Adv Med Oncol. 2019 Jul 12;11:1758835919861914. (PMID: 31320937)
Curr Protoc. 2021 Mar;1(3):e90. (PMID: 33780170)
Hepatology. 2020 Jan;71(1):93-111. (PMID: 31222801)
World J Gastroenterol. 2010 Feb 28;16(8):934-47. (PMID: 20180231)
Anticancer Res. 2012 Apr;32(4):1119-36. (PMID: 22493341)
J Hepatol. 2015 Jul;63(1):164-73. (PMID: 25703085)
Nat Genet. 2015 May;47(5):505-511. (PMID: 25822088)
Transl Gastroenterol Hepatol. 2019 May 17;4:33. (PMID: 31231700)
Genes Dev. 1999 Sep 1;13(17):2196-206. (PMID: 10485843)
Cancer Med. 2019 Mar;8(3):1054-1065. (PMID: 30791221)
Discov Med. 2014 Nov;18(100):255-63. (PMID: 25425466)
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. (PMID: 27141961)
Nat Rev Dis Primers. 2018 Apr 12;4:18017. (PMID: 29644994)
Biomed Res Int. 2014;2014:153867. (PMID: 24877058)
Int J Mol Sci. 2020 May 27;21(11):. (PMID: 32471201)
J Hepatol. 2018 Mar;68(3):526-549. (PMID: 28989095)
Int J Mol Sci. 2017 Jul 29;18(8):. (PMID: 28758927)
Liver Res. 2017 Dec;1(4):221-230. (PMID: 29977644)
Methods Mol Biol. 2012;786:359-94. (PMID: 21938637)
Int J Cancer. 2019 Dec 1;145(11):3140-3151. (PMID: 31020993)
Med Pharm Rep. 2019 Apr;92(2):99-105. (PMID: 31086834)
Dig Dis Sci. 2011 Feb;56(2):578-85. (PMID: 21046244)
Dig Dis. 2016;34(4):327-33. (PMID: 27170385)
Grant Information:
BT/HRD/35/02/2006 Department of Biotechnology, Ministry of Science and Technology, India
Contributed Indexing:
Keywords: HCC transcriptomics; autoimmune liver disease; gene regulatory network; hepatic fibrosis; hepatocellular carcinoma; liver cirrhosis
Substance Nomenclature:
0 (Biomarkers)
0 (Carrier Proteins)
0 (Membrane Proteins)
0 (Thyroid Hormones)
EC 2.3.1.20 (DGAT2 protein, human)
EC 2.3.1.20 (Diacylglycerol O-Acyltransferase)
EC 2.3.2.23 (DDB1 and CUL4 associated factor 11, human)
EC 2.3.2.23 (Ubiquitin-Protein Ligase Complexes)
EC 2.6.1. (BCAT1 protein, human)
EC 2.6.1.- (Transaminases)
Entry Date(s):
Date Created: 20210827 Date Completed: 20211203 Latest Revision: 20231213
Update Code:
20240104
PubMed Central ID:
PMC8394127
DOI:
10.3390/cells10081917
PMID:
34440687
Czasopismo naukowe
Autoimmune liver diseases (AILD) often lead to transformation of the liver tissues into hepatocellular carcinoma (HCC). Considering the drawbacks of surgical procedures in such cases, need of successful non-invasive therapeutic strategies and treatment modalities for AILD-associated-HCC still exists. Due to the lack of clear, sufficient knowledge about factors mediating AILD-to-HCC transition, an in silico approach was adopted to delineate the underlying molecular deterministic factors. Parallel enrichment analyses on two different public microarray datasets (GSE159676 and GSE62232) pinpointed the core transcriptional regulators as key players. Correlation between the expression kinetics of these transcriptional modules in AILD and HCC was found to be positive primarily with the advancement of hepatic fibrosis. Most of the regulatory interactions were operative during early (F0-F1) and intermediate fibrotic stages (F2-F3), while the extent of activity in the regulatory network considerably diminished at late stage of fibrosis/cirrhosis (F4). Additionally, most of the transcriptional targets with higher degrees of connectivity in the regulatory network (namely DCAF11, PKM2, DGAT2 and BCAT1) may be considered as potential candidates for biomarkers or clinical targets compared to their low-connectivity counterparts. In summary, this study uncovers new possibilities in the designing of novel prognostic and therapeutic regimen for autoimmunity-associated malignancy of liver in a disease progression-dependent fashion.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies